Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Kidney Transplant Failure and Rejection Clinical Trial

Official title:
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Status Completed

Clinical Trial Summary

The primary objective is to compare the effect of treatment with an immediate-release tacrolimus to an extended-release tacrolimus (i.e., Envarsus® XR) immunosuppressive regimen on cognitive and motor function in kidney transplant recipients

Clinical Trial Description

Between four (4) months and 14 months after receiving a kidney transplant and, per standard of care (SOC), having been placed on an immediate-release (IR) tacrolimus immunosuppressant regimen, participants in this study will undergo cognitive and motor function testing and have a blood sample collected (BASELINE). Half of the participants will then be randomly converted to extended-release (XR) tacrolimus (Envarsus® XR) while the other half will remain on IR tacrolimus for the duration of the study. Both the IR and XR groups will repeat the cognitive and motor function testing and have a blood sample collected at 6, 12, and 24 weeks Post-BASELINE. A practice version of the cognitive and motor function tests will be administered no more than 60 days prior to the baseline visit (Pre-BASELINE). Alternate versions of the cognitive and motor tests will be used at each Post-BASELINE testing session to control for possible practice effects. The primary objective is to compare the effect of treatment with an immediate-release tacrolimus to an extended-release tacrolimus (i.e., Envarsus® XR) immunosuppressive regimen on cognitive and motor function in kidney transplant recipients. The secondary objective is to determine the factors that explain inter-individual variability in cognitive response. Pharmacokinetic and demographic factors will be explored. Variability in cognitive response between individuals can be large. A population approach (nonlinear, mixed effects) will be used. Measurement of drug concentration will be the dependent variable. ;

Study Design

Related Conditions & MeSH terms

Kidney Transplant Failure and Rejection

Clinical Trial Details

NCT number	NCT03437577
Study type	Interventional
Source	University of Minnesota
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	May 8, 2018
Completion date	March 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04057742` - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
Recruiting	`NCT03465397` - Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients	Phase 4
Not yet recruiting	`NCT05282966` - Assessment of QSant™ for Underlying Allograft Rejection
Recruiting	`NCT04388930` - The Microbiota in Kidney Donation and Transplantation
Completed	`NCT03611621` - A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Recruiting	`NCT05397821` - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Completed	`NCT04019353` - Cf-DNA Assay During Treatment of Acute Rejection
Active, not recruiting	`NCT05806749` - Immunological Tolerance in Patients With Mismatched Kidney Transplants	Phase 1
Recruiting	`NCT04936282` - Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)	Phase 4
Enrolling by invitation	`NCT05285878` - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation	Phase 2
Recruiting	`NCT04526431` - Tacrolimus Pharmacokinetic Subpopulations
Active, not recruiting	`NCT03511560` - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation	Phase 4
Recruiting	`NCT03438773` - Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients	Phase 1
Completed	`NCT05388955` - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Completed	`NCT06394596` - Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
Completed	`NCT04413916` - MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
Completed	`NCT03466775` - Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes	N/A
Active, not recruiting	`NCT04733131` - Long-term Outcomes After Conversion to Belatacept
Active, not recruiting	`NCT03380962` - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant	Phase 1/Phase 2
Active, not recruiting	`NCT04154267` - Protocol Biopsies in High-risk Renal Transplant Recipients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.